GlassScriptPhysician profile
Michael L Weinstein
NPI 1881653012
$9,757.04
in general payments reported to CMS, 2019-2025
28 companies · $62.84 in 2025
The $62.84 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $2,137 · 2021: $1,498 · 2022: $1,673 · 2023: $962 · 2024: $1,228 · 2025: $62.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Debt Forgiveness: $719 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.17 |
| Debt Forgiveness | $718.98 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $2,174.73 | 2019-2022 | |
| Medtronic, INC. | $1,937.75 | 2021-2022 | |
| Eli Lilly and Company | $1,511.63 | 2019 | |
| Olympus America INC. | $718.98 | 2024 | Gastrointestinal Videoscope |
| Pentax of America, INC. | $556.71 | 2023 | Video Colonoscope |
| Boston Scientific Corporation | $491.26 | 2021-2024 | Speedband Superview Super 7 |
| Abbvie INC. | $354.18 | 2019-2023 | Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $231.01 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Celgene Corporation | $181.06 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $164.63 | 2024 | Dupixent |
| Genzyme Corporation | $134.74 | 2023 | |
| Ardelyx, INC. | $133.55 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.13 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $117.94 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $105.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.22 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $80.08 | 2019-2022 | |
| Exact Sciences Corporation | $72.88 | 2024 | Cologuard Collection Kit |
| Iterative Scopes, INC. | $62.84 | 2025 | Skout |
| Qol Medical, LLC | $57.12 | 2019 | |
| Ucb, INC. | $36.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $36.63 | 2022 | |
| Echosens North America, INC. | $28.98 | 2023 | Fibroscan |
| Allergan, INC. | $26.29 | 2019 | |
| Daiichi Sankyo INC. | $21.49 | 2023 | Injectafer |
| Braintree Laboratories, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.